Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.19209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vorinostat for treatment-refractory bullous pemphigoid.
J Eur Acad Dermatol Venereol
October 2023
Department of Dermatology , Lausanne University Hospital (CHUV), Lausanne, Switzerland and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
Oncotarget
September 2022
Beverly Hills Cancer Center, Beverly Hills, CA 90211, USA.
Classical MCL (cMCL) constitutes 6-8% of all B cell NHL. Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer subtype of cMCL associated with an aggressive clinical course and poor treatment response, frequent relapse and poor outcomes.
View Article and Find Full Text PDFA phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Invest New Drugs
December 2013
University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6/568 CSC, Madison, WI, 53792, USA,
Background: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors.
Methods: Patients received vorinostat orally once daily on days 1-14 and bortezomib intravenously on days 1, 4, 8 and 11 of a 21-day cycle. Starting dose (level 1) was vorinostat (400 mg) and bortezomib (0.
The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
J Drugs Dermatol
April 2011
Department of Dermatology, Ankara University School of Medicine, Turkey.
Objective: Long-term survival for advanced stages of mycosis fungoides (MF) may be beneficially affected by the use of multimodality therapy. We aim to evaluate the activity of vorinostat in combination with interferon (IFN) alpha and extracorporeal photopheresis (ECP) with persistent, progressive advanced stage MF and Sezary syndrome (SS).
Patients And Methods: Three patients with stage IIB-IVA MF/SS were treated with vorinostat 400 mg/day/po.
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Clin Lymphoma Myeloma
December 2009
Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Box 1492, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Introduction: Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies.
Patients And Methods: A multicenter, open-label phase IIb trial evaluated the activity and safety of vorinostat 400 mg orally daily in patients with > or = stage IB, persistent, progressive, or treatment-refractory mycosis fungoides or Sézary syndrome CTCL subtypes. We report the safety and tolerability of long-term vorinostat therapy in patients who experienced clinical benefit in the previous phase IIb study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!